Skip to main content

Table 2 Baseline characteristics of the study cohort, as a group and according to anti-Ro52/TRIM21 antibody status

From: Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis

  Whole group
(N = 963)
Anti-Ro52/TRIM21 antibody positive (n= 194) Anti-Ro52/TRIM21 antibody negative (n= 769) Odds ratio (95% CI) and Pvalues (Anti-Ro52/TRIM21 positive vs negative)
  Mean or n SD or % Mean or n SD or % Mean or n SD or %   
Age, years 55.42 12.04 57.16 11.45 54.98 12.16 1.02 (1.00, 1.03) 0.0481
Female, % 833 86.50% 175 90.21% 658 85.57% NS  
White, % 816 84.74% 160 82.47% 656 85.31% NS  
Disease duration, years 11.04 9.47 11.29 9.55 10.98 9.46 NS  
Disease subsets, %        NS  
   Limited disease 563 59.26% 121 62.69% 442 58.39%   
   Diffuse disease 356 37.47% 69 35.75% 287 37.91%   
   Sine scleroderma 31 3.26% 3 1.55% 28 3.70%   
Modified Rodnan skin score (range, 0-51) 10.02 9.47 9.68 8.53 10.11 9.69 NS  
Swollen-joint count
(range, 0-28)
0.91 3.34 1.07 4.26 0.87 3.07 NS  
Number of GI symptoms (range 0-14) 4.17 3.13 4.27 3.30 4.14 3.09 NS  
Inflammatory myositis, % 103 11.48% 21 11.54% 82 11.47% NS  
Thrombosis, % 29 3.06% 7 3.65% 22 2.91% NS  
Scleroderma renal crisis, % 42 4.44% 7 3.65% 35 4.64% NS  
Interstitial lung disease, % 342 36.19% 85 44.27% 257 34.13% 1.53 (1.11, 2.12) 0.0091
Pulmonary hypertension,% 96 11.72% 26 15.38% 70 10.77% NS  
Overlap with SLE, % 30 3.19% 8 4.23% 22 2.93% NS  
Overlap with Sjögren, % 63 6.70% 18 9.52% 45 5.98% NS  
Overlap with RA, % 30 3.19% 8 4.23% 22 2.93% NS  
Overlap with MCTD, % 20 2.13% 7 3.70% 13 1.73% NS  
Overlap with PM/DM, % 36 3.83% 12 6.35% 24 3.19% 2.06 (1.01, 4.19) 0.0431
Overlap syndrome, % 143 15.18% 41 21.58% 102 13.56% 1.75 (1.17, 2.63) 0.0059
  1. CI, confidence interval; GI, gastrointestinal; MCTD, mixed connective tissue disease; NS, not significant; overlap syndrome, overlap with systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, mixed connective tissue disease, and/or polymyositis/dermatomyositis; PM/DM, polymyositis/dermatomyositis; RA, rheumatoid arthritis; SD, standard deviation; SLE, systemic lupus erythematosus.